These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 20031678)

  • 1. Interference of drug-eluting stents with endothelium-dependent coronary vasomotion: evidence for device-specific responses.
    Hamilos M; Sarma J; Ostojic M; Cuisset T; Sarno G; Melikian N; Ntalianis A; Muller O; Barbato E; Beleslin B; Sagic D; De Bruyne B; Bartunek J; Wijns W
    Circ Cardiovasc Interv; 2008 Dec; 1(3):193-200. PubMed ID: 20031678
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential effects of drug-eluting stents on local endothelium-dependent coronary vasomotion.
    Hamilos MI; Ostojic M; Beleslin B; Sagic D; Mangovski L; Stojkovic S; Nedeljkovic M; Orlic D; Milosavljevic B; Topic D; Karanovic N; Wijns W;
    J Am Coll Cardiol; 2008 Jun; 51(22):2123-9. PubMed ID: 18510958
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bioabsorbable polymer-coated sirolimus-eluting stent implantation preserves coronary vasomotion: A DESSOLVE II trial sub-study.
    Rusinaru D; Vrolix M; Verheye S; Chowdhary S; Schoors D; Di Mario C; Desmet W; Donohoe DJ; Ormiston JA; Knape C; Bezerra H; Lansky A; Wijns W;
    Catheter Cardiovasc Interv; 2015 Dec; 86(7):1141-50. PubMed ID: 25044635
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of endothelium-dependent and -independent vasomotor response after abluminal biodegradable polymer biolimus-eluting stent and persistent polymer everolimus-eluting stent implantation (COMPARE-IT).
    Puricel S; Kallinikou Z; Espinola J; Arroyo D; Goy JJ; Stauffer JC; Baeriswyl G; Smits PC; Cook S; Togni M
    Int J Cardiol; 2016 Jan; 202():525-31. PubMed ID: 26440470
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Six-month comparison of coronary endothelial dysfunction associated with sirolimus-eluting stent versus Paclitaxel-eluting stent.
    Kim JW; Suh SY; Choi CU; Na JO; Kim EJ; Rha SW; Park CG; Seo HS; Oh DJ
    JACC Cardiovasc Interv; 2008 Feb; 1(1):65-71. PubMed ID: 19393147
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sirolimus-eluting stents associated with paradoxic coronary vasoconstriction.
    Togni M; Windecker S; Cocchia R; Wenaweser P; Cook S; Billinger M; Meier B; Hess OM
    J Am Coll Cardiol; 2005 Jul; 46(2):231-6. PubMed ID: 16022947
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Coronary vasomotion one year after drug-eluting stent implantation: comparison of everolimus-eluting and paclitaxel-eluting coronary stents.
    Hamilos M; Ribichini F; Ostojic MC; Ferrero V; Orlic D; Vassanelli C; Karanovic N; Sarno G; Cuisset T; Vardas PE; Wijns W
    J Cardiovasc Transl Res; 2014 Jun; 7(4):406-12. PubMed ID: 24794876
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term coronary endothelial function after zotarolimus-eluting stent implantation. A 9 month comparison between zotarolimus-eluting and sirolimus-eluting stents.
    Shin DI; Seung KB; Kim PJ; Chang K; Choi JK; Jeon DS; Kim MJ; Lee MY; Chung WS
    Int Heart J; 2008 Nov; 49(6):639-52. PubMed ID: 19075480
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Local vascular dysfunction after coronary paclitaxel-eluting stent implantation.
    Togni M; Räber L; Cocchia R; Wenaweser P; Cook S; Windecker S; Meier B; Hess OM
    Int J Cardiol; 2007 Aug; 120(2):212-20. PubMed ID: 17234280
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Specific coronary drug-eluting stents interfere with distal microvascular function after single stent implantation in pigs.
    van den Heuvel M; Sorop O; Batenburg WW; Bakker CL; de Vries R; Koopmans SJ; van Beusekom HM; Duncker DJ; Danser AH; van der Giessen WJ
    JACC Cardiovasc Interv; 2010 Jul; 3(7):723-30. PubMed ID: 20650434
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A prospective, randomized, 6-month comparison of the coronary vasomotor response associated with a zotarolimus- versus a sirolimus-eluting stent: differential recovery of coronary endothelial dysfunction.
    Kim JW; Seo HS; Park JH; Na JO; Choi CU; Lim HE; Kim EJ; Rha SW; Park CG; Oh DJ
    J Am Coll Cardiol; 2009 May; 53(18):1653-9. PubMed ID: 19406340
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Head-to-head comparison of sirolimus-eluting stent versus bare metal stent evaluation of the coronary endothelial dysfunction in the same patient presenting with multiple coronary artery lesions: the CREDENTIAL study.
    Mischie AN; Nazzaro MS; Fiorilli R; De Felice F; Musto C; Confessore P; Parma A; Boschetti C; Violini R
    Catheter Cardiovasc Interv; 2013 Sep; 82(3):E184-91. PubMed ID: 23359371
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug-eluting stent implantation could be associated with long-term coronary endothelial dysfunction.
    Shin DI; Kim PJ; Seung KB; Kim DB; Kim MJ; Chang K; Lim SM; Jeon DS; Chung WS; Baek SH; Lee MY
    Int Heart J; 2007 Sep; 48(5):553-67. PubMed ID: 17998765
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nobori stent shows less vascular inflammation and early recovery of endothelial function compared with Cypher stent.
    Pendyala LK; Matsumoto D; Shinke T; Iwasaki T; Sugimoto R; Hou D; Chen JP; Singh J; King SB; Chronos N; Li J
    JACC Cardiovasc Interv; 2012 Apr; 5(4):436-44. PubMed ID: 22516402
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endothelial function rather than endothelial restoration is altered in paclitaxel- as compared to bare metal-, sirolimusand tacrolimus-eluting stents.
    van Beusekom HM; Sorop O; van den Heuvel M; Onuma Y; Duncker DJ; Danser AH; van der Giessen WJ
    EuroIntervention; 2010 May; 6(1):117-25. PubMed ID: 20542807
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preserved endothelial vasomotor function after everolimus-eluting stent implantation.
    Roura G; Homs S; Ferreiro JL; Gomez-Lara J; Romaguera R; Teruel L; Sánchez-Elvira G; Ariza-Solé A; Gómez-Hospital JA; Cequier Á
    EuroIntervention; 2015 Oct; 11(6):643-9. PubMed ID: 25022229
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of stenting and oral sirolimus on endothelium-dependent and independent coronary vasomotion.
    Fernandes RW; Dantas JM; Oliveira DC; Bezerra HG; Brito FS; Lima VC
    Arq Bras Cardiol; 2012 Apr; 98(4):290-8. PubMed ID: 22406990
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Abnormal vasomotor function of porcine coronary arteries distal to sirolimus-eluting stents.
    Li J; Jabara R; Pendyala L; Otsuka Y; Shinke T; Hou D; Robinson K; Chronos N
    JACC Cardiovasc Interv; 2008 Jun; 1(3):279-85. PubMed ID: 19463313
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized comparison of the Nobori Biolimus A9-eluting coronary stent with the Taxus Liberté paclitaxel-eluting coronary stent in patients with stenosis in native coronary arteries: the NOBORI 1 trial--Phase 2.
    Chevalier B; Silber S; Park SJ; Garcia E; Schuler G; Suryapranata H; Koolen J; Hauptmann KE; Wijns W; Morice MC; Carrie D; van Es GA; Nagai H; Detiege D; Paunovic D; Serruys PW;
    Circ Cardiovasc Interv; 2009 Jun; 2(3):188-95. PubMed ID: 20031715
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vasomotor Function Comparative Assessment at 1 and 2 Years Following Implantation of the Absorb Everolimus-Eluting Bioresorbable Vascular Scaffold and the Xience V Everolimus-Eluting Metallic Stent in Porcine Coronary Arteries: Insights From In Vivo Angiography, Ex Vivo Assessment, and Gene Analysis at the Stented/Scaffolded Segments and the Proximal and Distal Edges.
    Gogas BD; Benham JJ; Hsu S; Sheehy A; Lefer DJ; Goodchild TT; Polhemus DJ; Bouchi YH; Hung OY; Yoo SY; Joshi U; Giddens DP; Veneziani A; Quyyumi A; Rapoza R; King SB; Samady H
    JACC Cardiovasc Interv; 2016 Apr; 9(7):728-41. PubMed ID: 27056313
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.